• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

IPILIMUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • IPILIMUMAB chembl:CHEMBL1789844 ApprovedAntineoplastic

    Alternate Names:

    YERVOY
    IPILIMUMAB
    MDX-101
    BMS-734016
    MDX-010
    MDX-CTLA-4
    MOAB-CTLA-4
    drugbank:06186
    chembl:CHEMBL1789844
    chemidplus:477202-00-9
    rxcui:1094833

    Drug Info:

    FDA Approval Melanoma
    Drug Class Therapeutic Antibodies
    FDA Approval approved
    Drug Class monoclonal antibody
    Drug Indications antineoplastic agent
    Pharmaceutical Developer Bristol-Myers Squibb
    Source Reported Drug Name(s) Yervoy/ipilimumab
    Drug Categories adjuvants, immunologic
    Drug Categories antibodies, monoclonal, humanized
    Drug Categories antineoplastic agents, immunological
    Drug Categories ctla-4-directed antibody interactions
    Drug Categories ctla-4-directed blocking antibody
    Drug Categories drugs that are mainly renally excreted
    Drug Categories immunoglobulin g
    Drug Categories increased t lymphocyte activation
    Drug Categories narrow therapeutic index drugs
    (9 More Sources)

    Publications:

    Yang et al., Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis., J. Immunother.
    Tsao SC et al., 2015, Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations., Sci Rep
    Miao D et al., 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma., Science
    Kato et al., 2017, Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate., Clin. Cancer Res.
  • IPILIMUMAB   CTLA4

    Interaction Score: 6.31

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Endogenous Drug? False
    Specific Action of the Ligand Binding
    Direct Interaction? True

    PMIDs:
    18049334


    Sources:
    TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions GuideToPharmacology CancerCommons TTD

  • IPILIMUMAB   PBRM1

    Interaction Score: 2.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29301960


    Sources:
    CIViC

  • IPILIMUMAB   HLA-A

    Interaction Score: 1.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • IPILIMUMAB   MDM2

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28351930


    Sources:
    CIViC

  • IPILIMUMAB   NRAS

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26095797


    Sources:
    CIViC

  • DrugBank: DB06186

    • Version: 5.1.7

    Alternate Names:
    IPILIMUMAB DrugBank Drug Name
    477202-00-9 CAS Number
    Yervoy Drug Brand

    Drug Info:
    Drug Type biotech
    Drug Groups approved
    Drug Categories adjuvants, immunologic

    Publications:
    Yang et al., Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis., J. Immunother.

  • MyCancerGenome: IPILIMUMAB

    • Version: 20-Jun-2017

    Alternate Names:
    MDX-010 Development Name
    MDX-101 Development Name
    BMS-734016 Development Name

    Drug Info:
    Drug Class Therapeutic Antibodies
    FDA Approval Melanoma

    Publications:

  • CancerCommons: IPILIMUMAB

    • Version: 25-July-2013

    Alternate Names:
    Yervoy Drug Trade Name
    Ipilimumab Drug Development Name

    Drug Info:
    Drug Class Monoclonal Antibody
    Source Reported Drug Name(s) Yervoy/ipilimumab
    Pharmaceutical Developer Bristol-Myers Squibb

    Publications:

  • TdgClinicalTrial: IPILIMUMAB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class monoclonal antibody
    FDA Approval approved

    Publications:

  • CIViC: IPILIMUMAB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tsao SC et al., 2015, Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations., Sci Rep
    Kato et al., 2017, Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate., Clin. Cancer Res.
    Miao D et al., 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma., Science

  • TTD: Ipilimumab

    • Version: 2020.06.01

    Alternate Names:
    D07BVI TTD Drug ID

    Drug Info:

    Publications:

  • TALC: IPILIMUMAB

    • Version: 12-May-2016

    Alternate Names:
    IPILIMUMAB Primary Drug Name
    IPILIMUMAB Drug Generic Name
    YERVOY Drug Trade Name

    Drug Info:

    Publications:

  • GuideToPharmacology: 178103470

    • Version: 29-September-2020

    Alternate Names:
    IPILIMUMAB GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1789844

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1789844

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: IPILIMUMAB

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: ipilimumab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Ipilimumab

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21